Clinical Trials Logo

Healthy Volunteers clinical trials

View clinical trials related to Healthy Volunteers.

Filter by:

NCT ID: NCT01497288 Completed - Healthy Volunteers Clinical Trials

A Trial to Investigate the Pharmacokinetics (PK) of Single Doses of 200 µg, 400 µg and 2 x 400 µg of Intranasal Fentanyl Spray (INFS) in Healthy Subjects

PK400 INFS
Start date: November 2011
Phase: Phase 1
Study type: Interventional

The overall clinical trial objective is to gain information about the Pharmacokinetics (PK) of a 400 µg dose strength of INFS using a Population PK (PopPK). In total, 20 healthy male and female subjects are planned to be randomized in the trial. Subjects will be randomized to one of two treatment sequences and treated with 3 different dosages (either 200 µg/dose INFS, 400 µg/dose or 400 µg two doses administered 10 minutes apart) over two days. Subjects will be hospitalized over a period of total 5 days, where safety assessments and pharmacokinetic samplings will be conducted.

NCT ID: NCT01496911 Completed - Healthy Volunteers Clinical Trials

Effects of Levocetirizine and Hydroxyzine on Cognitive and Psychomotor Functioning During Simulated Diving

Start date: April 2012
Phase: Phase 4
Study type: Interventional

Antihistamines are commonly used and currently levocetirizine is most frequently prescribed in the Netherlands. They are commonly used by divers, to solve ear, nose and throat problems, especially to open tubal passage. However, the effects of these drugs on cognitive performance have not been investigated during diving.The objective of this study is to investigate the effects of levocetirizine, hydroxyzine and placebo on cognitive and psychomotor functioning during controlled simulated diving in a hyperbaric chamber in professional navy divers at 10 mt (2 bar) and 30 mt (4 bar).It is hypothesized that hydroxyzine will produce significant impairment, and that the magnitude of impairment is related to hyperbaric pressure.

NCT ID: NCT01496755 Completed - Healthy Volunteer Clinical Trials

A Study of RG7667 in Healthy Volunteers

Start date: January 2012
Phase: Phase 1
Study type: Interventional

This randomized, double-blind, placebo-controlled study will evaluate the safety and pharmacokinetics of RG7667 in healthy volunteers. Subjects will be randomized in cohorts to receive either single/multiple doses of RG7667 intravenously or placebo. Anticipated time on study treatment is up to 57 days with a 12-week follow-up.

NCT ID: NCT01495104 Completed - Healthy Volunteer Clinical Trials

A Study on the Effects of Valproate on the Pharmacokinetics of RO4917838 in Healthy Volunteers

Start date: October 2011
Phase: Phase 1
Study type: Interventional

This open-label, fixed-sequence, two-period study will assess the effect of multiple dose valproate on the pharmacokinetics of RO4917838 at steady state and vice versa in healthy male volunteers. In Period 1, subjects will receive valproate for 5 days. After a washout period of 5 days to 2 weeks, subjects will receive, in Period 2, RO4917838 for 15 days with concomitant valproate on Days 11-15. Anticipated time on study is up to 12 weeks.

NCT ID: NCT01494714 Completed - Healthy Volunteers Clinical Trials

A Study to Evaluate Skin Irritation and Photo Irritation of JNJ 10229570-AAA on Intact Skin of Japanese Healthy Male Participants

Start date: August 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate skin irritation and photo irritation of JNJ 10229570-AAA on intact skin of Japanese healthy male participants.

NCT ID: NCT01493856 Completed - Healthy Volunteers Clinical Trials

A Clinical Trial to Compare the Safety and Pharmacokinetic Characteristics of Combination of Rosuvastatin and CS-866 and DWJ1276

Start date: January 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and pharmacokinetic characteristics of combination of rosuvastatin and CS-866 and DWJ1276 alone.

NCT ID: NCT01493804 Completed - Healthy Volunteers Clinical Trials

Noninvasive Study of Brain Connectivity With EEG and NIRS

Start date: November 8, 2011
Phase: N/A
Study type: Observational

Background: - Different regions of the brain are activated when a person performs a task. Electroencephalograms (EEGs) and near-infrared spectroscopy (NIRS) are tests that detect changes in the brain. EEG looks at changes in electrical signals, and NIRS looks at changes in blood flow. These tests can detect local changes in brain activity in a safe and noninvasive way. Researchers want to study brain activity more closely by combining these tests. Objectives: - To use EEG and NIRS to study brain activity during specific tasks. Eligibility: - Healthy volunteers at least 18 years of age. Design: - Participants will be screened with a physical exam and medical history. - Participants will have between one and five testing sessions. Each session will be 1 to 2 hours long. The tests given at each session will be determined by the researchers. - Participants will have EEG and NIRS tests, given either separately or together. During these tests, participants will perform tasks of thinking and reasoning. - Participants may also complete optional tests of thinking and reasoning. These tests will be given on paper or on a computer.

NCT ID: NCT01492933 Terminated - Healthy Volunteers Clinical Trials

Measuring Effects of Alcohol on Brain Chemistry

Start date: November 22, 2011
Phase:
Study type: Observational

Background: - Studies show that alcohol changes the amount of many brain chemicals. These changes may be related to continued drinking, craving for alcohol, and relapse. This study will use magnetic resonance imaging (MRI) to look at brain areas and brain chemistry during an infusion of alcohol. It will also study how changes in brain chemistry relate to participant reports of feeling drunk. Objectives: - To use magnetic resonance imaging to measure the effect of alcohol on brain chemistry Eligibility: - Individuals between 21 and 45 years of age. - Participants will be either light drinkers (1 to 14 standard alcoholic drinks per week) or heavy drinkers (20 to 40 standard alcoholic drinks per week). A standard drink is a 12-ounce beer, a 4-ounce glass of wine, or a shot of liquor. - Participants must be able to go without alcohol for at least 3 days in a row without severe withdrawal symptoms. Design: - This study requires two or three outpatient visits to the NIH Clinical Center. - Participants will have a physical exam and medical history. Blood and urine samples will be collected. Participants' alcohol drinking habits will also be assessed to determine whether they may have an alcohol use disorder. - At the first study visit, participants will have an infusion of alcohol. Blood samples will be collected to measure blood alcohol levels. - The MRI study visit will take place about 3 days after the first study visit. Participants will have an MRI scan of the brain, followed by an infusion of alcohol and another scan. Blood samples will be collected. - Participants will complete questionnaires before and after each infusion to measure their response to alcohol. - Heavy drinkers will come to the clinic for a third visit to discuss possible future treatment and any risky behavior associated with their high levels of alcohol use.

NCT ID: NCT01489592 Completed - Healthy Volunteers Clinical Trials

Effect of Curcumin on Iron Metabolism in Healthy Volunteer

CURHEP
Start date: October 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the impact of curcumin, administrated orally, on iron metabolism in healthy volunteers. Iron metabolism will be describe by hepcidin expression that the investigators observed in vitro and serum hepcidin levels.

NCT ID: NCT01487564 Completed - Healthy Volunteers Clinical Trials

Pharmacokinetic Profile of OROS Hydromorphone in Healthy Taiwanese Participants With Different Genotypes for the UGT2B7 Gene

Start date: October 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate the pharmacokinetics of OROS hydromorphone in healthy adult Taiwanese participants after the oral administration of a single 16 mg dose.